Ali Erginay · enciclopedia

Publicaciones › Edema macular diabético y sus tratamientos

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy

Eficacia del implante de 0,2 μg/día de acetónido de fluocinolona (ILUVIEN) en ojos con edema macular diabético y vitrectomía previa

Año2017
FuenteEye (London, England)
Tipoarticle · Journal Article
Autores (12)A Meireles, C Goldsmith, I El-Ghrably, A Erginay, M Habib, B Pessoa, J Coelho, T Patel, R Tadayoni, P Massin, J Atorf, A J Augustin
Posición de Erginay4 de 12
Citas42 (OpenAlex)
EnlacesDOI 10.1038/eye.2016.303 · PubMed 28085139 · OpenAlex · Texto completo en acceso abierto
LíneasEdema macular diabético y sus tratamientos Interfase vitreomacular, agujero macular y miopía alta Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió la eficacia del implante de acetónido de fluocinolona en 26 ojos con edema macular diabético que habían sido sometidos a vitrectomía previamente. Los resultados mostraron una mejora en la agudeza visual y una reducción en el grosor de la mácula. El implante demostró ser efectivo y seguro en estos pacientes.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

PurposeLimited data are available on the efficacy of the 0.2 μg/day fluocinolone acetonide (FAc) implant in eyes with prior vitrectomy. Here, we present a collection of 26 vitrectomized eyes treated with the 0.2 μg/day FAc implant.MethodsRetrospective study involving six centers from four European countries analyzing the safety and efficacy data from patients (26 eyes from 25 patients) with DME and a prior vitrectomy that had been treated with one 0.2 μg/day FAc implant.ResultsPrior intravitreal therapies included anti-VEGF (mean, 3.8 injections) and steroids (mean, 1.9 injections). Pars plana vitrectomy (PPV) was performed in these eyes primarily for abnormalities of vitreoretinal interface, followed by proliferative diabetic retinopathy and vitreous hemorrhage. The 0.2 μg/day FAc implant was injected 24.2 months, on average, after PPV and the mean duration of follow-up after injection was 255 days (range, 90 to 759 days). The mean change in BCVA was +11.7 ETDRS letters (range, -19 to +40 letters; P<0.0004) and the mean change in central foveal thickness (CFT) was -233.5 μm (range, -678 to 274 μm; P<0.0001). The mean change in IOP from baseline at the last visit was +1.4 mm Hg (range, -9 to +8 mm Hg; P=0.0090). Eight eyes initiated or continued IOP lowering medications.ConclusionsThese data suggest the 0.2 μg/day FAc implant is effective in vitrectomized patients with an acceptable safety profile. Further studies are still required to confirm the current findings and to assess the effect of the 0.2 μg/day FAc implant over a longer period of follow-up.

Términos MeSH

Aged Diabetic Retinopathy Dose-Response Relationship, Drug Drug Implants Female Fluocinolone Acetonide Follow-Up Studies Glucocorticoids Humans Intravitreal Injections Macula Lutea Macular Edema Male Preoperative Period Retrospective Studies Time Factors Tomography, Optical Coherence Treatment Outcome Visual Acuity Vitrectomy